We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cancer research
An SI Board Since July 2014
Posts SubjectMarks Bans Symbol
0 1 0 GNSZ
Emcee:  Jerseyfish Type:  Moderated
GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei



SAN ANTONIO, July 7, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13th in Taipei, Taiwan.

An oral presentation entitled, "Clinical Activity of G-202, a Thapsigargin-Based Prostate-Specific Membrane Antigen (PSMA)-Activated Prodrug, in Patients with Progressive Hepatocellular Carcinoma (HCC)" will be presented in the poster discussion session "Treatment for Intermediate – Advanced Stage Disease" on July 12th from 1:15- 3:00 pm UTC + 8:00.

Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC), will discuss the data obtained to date in patients with HCC treated in the Phase I and Phase II studies. Dr. Mahalingam is an oncologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, specializing in identifying novel cancer therapeutics.

The abstract will be published on the company website following the APPLE Poster Session.

 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):